Indaptus Therapeutics Inc

Company Profile

Indaptus Therapeutics Inc had its IPO on 2015-08-04 under the ticker symbol INDP.

The company operates in the Healthcare sector and Biotechnology industry. Indaptus Therapeutics Inc has a staff strength of 6 employees.

Stock update

Shares of Indaptus Therapeutics Inc opened at $3.08 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.98 - $3.12, and closed at $3.06.

This is a -0.33% slip from the previous day's closing price.

A total volume of 4,697 shares were traded at the close of the day’s session.

In the last one week, shares of Indaptus Therapeutics Inc have increased by +4.08%.

Indaptus Therapeutics Inc's Key Ratios

Indaptus Therapeutics Inc has a market cap of $24.70 million, indicating a price to book ratio of 0.5213 and a price to sales ratio of 0.

In the last 12-months Indaptus Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-15588645. The EBITDA ratio measures Indaptus Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Indaptus Therapeutics Inc’s operating margin was 0% while its return on assets stood at -35.49% with a return of equity of -59.63%.

In Q2, Indaptus Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Indaptus Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.9 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Indaptus Therapeutics Inc’s profitability.

Indaptus Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.9962. Its price to sales ratio in the trailing 12-months stood at 0.

Indaptus Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$20.84 million

Total Liabilities

$2.10 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Indaptus Therapeutics Inc ended 2024 with $20.84 million in total assets and $0 in total liabilities. Its intangible assets were valued at $20.84 million while shareholder equity stood at $18.63 million.

Indaptus Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $2.10 million in other current liabilities, 84011.00 in common stock, $-37491988.00 in retained earnings and $0 in goodwill. Its cash balance stood at $12.70 million and cash and short-term investments were $19.69 million. The company’s total short-term debt was $100,421 while long-term debt stood at $0.

Indaptus Therapeutics Inc’s total current assets stands at $19.87 million while long-term investments were $0 and short-term investments were $6.99 million. Its net receivables were $0 compared to accounts payable of $747674.00 and inventory worth $0.

In 2024, Indaptus Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Indaptus Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$3.06

52-Week High

$3.19

52-Week Low

$1.25

Analyst Target Price

$8

Indaptus Therapeutics Inc stock is currently trading at $3.06 per share. It touched a 52-week high of $3.19 and a 52-week low of $3.19. Analysts tracking the stock have a 12-month average target price of $8.

Its 50-day moving average was $2.23 and 200-day moving average was $1.95 The short ratio stood at 1.51 indicating a short percent outstanding of 0%.

Around 3014.8% of the company’s stock are held by insiders while 689.7% are held by institutions.